Catalytic iron and acute kidney injury.

Acute kidney injury (AKI) is a common and often devastating condition among hospitalized patients and is associated with markedly increased hospital length of stay, mortality, and cost. The pathogenesis of AKI is complex, but animal models support an important role for catalytic iron in causing AKI. Catalytic iron, also known as labile iron, is a transitional pool of non-transferrin-bound iron that is readily available to participate in redox cycling. Initial findings related to catalytic iron and animal models of kidney injury have only recently been extended to human AKI. In this review, we discuss the role of catalytic iron in human AKI, focusing on recent translational studies in humans, assay considerations, and potential therapeutic targets for future interventional studies.

[1]  G. Mufti,et al.  Bleomycin‐detectable iron in serum from leukaemic patients before and after chemotherapy Therapeutic implications for treatment with oxidant‐generating drugs , 1988, FEBS letters.

[2]  S. Shah,et al.  Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. , 1988, The Journal of clinical investigation.

[3]  M. Paller Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. , 1988, The American journal of physiology.

[4]  B. Hedlund,et al.  Role of iron in postischemic renal injury in the rat. , 1988, Kidney international.

[5]  P. Menasché,et al.  Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man. , 1988, The Journal of thoracic and cardiovascular surgery.

[6]  P. Menasché,et al.  Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. , 1990, Circulation.

[7]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[8]  J. Eaton,et al.  Ferritin: a cytoprotective antioxidant strategem of endothelium. , 1992, The Journal of biological chemistry.

[9]  G. Vercellotti,et al.  Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. , 1992, The Journal of clinical investigation.

[10]  R. Zager Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. , 1992, The Journal of clinical investigation.

[11]  S. Shah,et al.  Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. , 1993, The Biochemical journal.

[12]  Steven S. Vogel,et al.  Using Caged Calcium to Study Sea Urchin Egg Cortical Granule Exocytosis in Vitro , 1994 .

[13]  B. Halliwell,et al.  Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. , 1994, Methods in enzymology.

[14]  S. Shah,et al.  Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. , 1996, Kidney international.

[15]  R. Hotchkiss,et al.  Endothelial cell apoptosis is accelerated by inorganic iron and heat via an oxygen radical dependent mechanism. , 1997, Surgery.

[16]  J. Olson,et al.  Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin , 1998, Nature Biotechnology.

[17]  S. Shah,et al.  In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. , 1998, Kidney international.

[18]  R. P. Cochran,et al.  Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels. , 1999, Journal of the American Society of Nephrology : JASN.

[19]  P. Ponka Cell biology of heme. , 1999, The American journal of the medical sciences.

[20]  M. Burkitt,et al.  A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the 'catalytic iron index' and its value in the assessment of iron status in haemochromatosis. , 2001, Clinical science.

[21]  J. Eaton,et al.  Pro-oxidant and cytotoxic effects of circulating heme. , 2002, Blood.

[22]  P. Guyre,et al.  Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. , 2003, Atherosclerosis.

[23]  A. Kausz,et al.  Predictors of ARF after cardiac surgical procedures. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  Z. Cabantchik,et al.  Labile plasma iron in iron overload: redox activity and susceptibility to chelation. , 2003, Blood.

[25]  M. Mitsnefes,et al.  J Am Soc Nephrol 15: 3073–3082, 2004 Amelioration of Ischemic Acute Renal Injury by Neutrophil , 2004 .

[26]  W. Buurman,et al.  Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury1 , 2004, Transplantation.

[27]  Joseph V Bonventre,et al.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  D. Tsiapras,et al.  Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. , 2005, European heart journal.

[29]  E. McCarthy,et al.  Declining mortality in patients with acute renal failure, 1988 to 2002. , 2006, Journal of the American Society of Nephrology : JASN.

[30]  P. Buehler,et al.  CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. , 2006, Blood.

[31]  C. Rapisarda,et al.  Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera , 2007, JBIC Journal of Biological Inorganic Chemistry.

[32]  S. Waikar,et al.  The incidence and prognostic significance of acute kidney injury. , 2007, Current opinion in nephrology and hypertension.

[33]  André M. N. Silva,et al.  Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. , 2009, Biochimica et biophysica acta.

[34]  A. Coutinho,et al.  Heme oxygenase-1 affords protection against noncerebral forms of severe malaria , 2009, Proceedings of the National Academy of Sciences.

[35]  M. Podinovskaia,et al.  Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin‐bound iron , 2010, Annals of the New York Academy of Sciences.

[36]  Sudhir V. Shah,et al.  The role of catalytic iron in acute kidney injury. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[37]  P. Buehler,et al.  Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. , 2012, The Journal of clinical investigation.

[38]  P. Brissot,et al.  Non-transferrin bound iron: a key role in iron overload and iron toxicity. , 2012, Biochimica et biophysica acta.

[39]  L. Vesterlund,et al.  Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. , 2012, Biochemical and biophysical research communications.

[40]  F. Dal-Pizzol,et al.  The Effects of N‐Acetylcysteine and Deferoxamine on Plasma Cytokine and Oxidative Damage Parameters in Critically Ill Patients With Prolonged Hypotension: A Randomized Controlled Trial , 2012, Journal of clinical pharmacology.

[41]  M. Rajapurkar,et al.  Impact of catalytic iron on mortality in patients with acute coronary syndrome exposed to iodinated radiocontrast-The Iscom Study. , 2013, American heart journal.

[42]  Anupam Agarwal,et al.  Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. , 2013, The Journal of clinical investigation.

[43]  Comparison of Bleomycin-Detectable Iron and Labile Plasma Iron Assays , 2013 .

[44]  P. Buehler,et al.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. , 2013, Blood.

[45]  D. Swinkels,et al.  Iron metabolism in the pathogenesis of iron-induced kidney injury , 2013, Nature Reviews Nephrology.

[46]  D. Leaf,et al.  Plasma catalytic iron, AKI, and death among critically ill patients. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[47]  C. Geisler,et al.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. , 2014, Blood.

[48]  Z. Cabantchik Labile iron in cells and body fluids: physiology, pathology, and pharmacology , 2014, Front. Pharmacol..

[49]  Haptoglobin Therapy Prevents Kidney Injury in Stored Blood Resuscitation of Murine Hemorrhagic Shock , 2014 .

[50]  K. Nath Heme oxygenase-1 and acute kidney injury , 2014, Current opinion in nephrology and hypertension.

[51]  F. Hsiao,et al.  Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events , 2014, Pharmacoepidemiology and drug safety.

[52]  A. Kamal,et al.  Macrophage and epithelial cell H-ferritin expression regulates renal inflammation , 2015, Kidney international.

[53]  D. Leaf,et al.  Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery. , 2015, Kidney international.

[54]  D. Leaf,et al.  Intraoperative High-Dose Dexamethasone and Severe AKI after Cardiac Surgery. , 2015, Journal of the American Society of Nephrology : JASN.

[55]  D. Leaf,et al.  Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery. , 2016, Journal of the American Society of Nephrology : JASN.

[56]  D. Swinkels,et al.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders , 2016, Haematologica.